News Releases

Summary Toggle Krystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic Fibrosis

Confirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespective of modulator-status; percentage of conducting airway cells transduced in each patient ranged

January 8, 2026

PDF Version
Summary Toggle Krystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic Fibrosis

Investor call to be held January 8 at 4:30 pm ET to discuss data update and next steps PITTSBURGH , Jan. 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026 ,

January 7, 2026

PDF Version
Summary Toggle Krystal Biotech to Present at 44th Annual J.P. Morgan Healthcare Conference

PITTSBURGH , Jan. 05, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 44 th Annual J.P. Morgan Healthcare Conference on January 12, 2026 , in San Francisco . Krish S.

January 5, 2026

PDF Version
Summary Toggle Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

PITTSBURGH , Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8 th Annual Evercore Healthcare Conference on December 3, 2025 , in Miami . Krish S. Krishnan , Chairman and Chief Executive Officer, will

November 26, 2025

PDF Version
Summary Toggle Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results

$97.8 million in 3Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in 4Q Updated U.S. VYJUVEK label expands eligible patient population and provides greater patient flexibility FDA grants platform technology designation CF

November 3, 2025

PDF Version
Summary Toggle Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

PITTSBURGH , Oct. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025, prior to the open of U.S. markets. The Company’s management will also host a conference call

October 21, 2025

PDF Version
Summary Toggle Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis

PITTSBURGH , Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology designation to the genetically modified, non-replicating herpes simplex virus type 1 (HSV-1)

October 14, 2025

PDF Version
Summary Toggle Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH , Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) approved a

September 15, 2025

PDF Version
Summary Toggle Krystal Biotech to Present at Cantor Global Healthcare Conference 2025

PITTSBURGH , Sept. 02, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Cantor Global Healthcare Conference 2025 on September 4, 2025 , in New York . Krish S. Krishnan , Chairman and Chief Executive Officer, will

September 2, 2025

PDF Version
Summary Toggle Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

PITTSBURGH , Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company’s redosable immunotherapy designed to drive sustained, localized expression of

August 21, 2025

PDF Version

Investors

News Releases